Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (QTRX) is a leader in ultra-sensitive digital immunoassay technology, enabling groundbreaking advancements in precision diagnostics and life sciences research. This dedicated news hub provides investors and industry professionals with comprehensive updates on the company's scientific developments and strategic initiatives.
Access timely, verified information about Quanterix's product innovations, research collaborations, and financial performance. Our curated collection includes earnings announcements, technology milestones, regulatory updates, and strategic partnerships that demonstrate the company's impact on biomarker detection capabilities.
Stay informed about QTRX's progress in commercializing its Simoa platform and expanding applications in neurological disorders, oncology, and infectious disease research. All content is meticulously organized to help stakeholders track the company's role in advancing next-generation diagnostic solutions.
Bookmark this page for direct access to official Quanterix communications and third-party analyses. Regularly updated with material developments, this resource supports informed decision-making about one of healthcare's most innovative diagnostic technology providers.
Quanterix (NASDAQ: QTRX), a leader in biomarker detection technology, announced that its CEO, Masoud Toloue, will participate in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for May 29, 2024, at 11:40 a.m. ET and will be available via a live webcast.
Replays will be accessible for a time post-conference. For more details, visit Quanterix’s official website.
Quanterix , a biomarker detection company, reported financial results for Q1 2024 with revenue of $32.1 million, a 12.7% increase year-over-year. The company is focused on developing new assays to detect neuro-pathologies like Alzheimer's, Parkinson's, and Multiple Sclerosis. Key highlights include the launch of a blood test for Alzheimer's and maintaining a strong cash position. The company reaffirmed its 2024 financial guidance with revenue expected in the range of $139 to $144 million.
Quanterix (NASDAQ: QTRX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results. The press release will be issued on May 7, 2024, after the market closes. Interested investors can access the webcast and dial-in information on the Quanterix website.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
